Nicole A Cipriani1, Michael G White2, Peter Angelos2, Raymon H Grogan3. 1. Department of Pathology, The University of Chicago, Chicago, Illinois. 2. Endocrine Surgery Research Program Department of Surgery, The University of Chicago, Chicago, Illinois. 3. Department of Endocrine Surgery, Baylor St. Luke's Medical Center, Houston, Texas.
Abstract
Background: Management of large thyroid nodules is controversial, as data are conflicting regarding overall rates of malignancy (ROM) in all nodules and frequency of false-negative fine-needle aspiration results (FNR) in cytologically benign nodules. This meta-analysis aimed to evaluate and compare ROM and FNR in small versus large nodules published in the literature. Methods: Articles indexed in PubMed, written in English, published electronically or in print on or prior to December 8 2017 were searched for "false negative thyroid size or cm" and "malignancy rates benign thyroid nodules." Three hundred fifty-two unique citations were identified. Multiple reviewers selected a final set of 35 articles that contained nodules stratified by size (3, 4, or 5 cm), with benign or all cytologic diagnoses, and with postsurgical histologic diagnoses. Multiple observers extracted data, including numbers of total, cytologically benign, and histologically malignant nodules. Size cutoffs of 3, 4, and/or 5 cm were analyzed in 14, 24, and 1 article, respectively. Results: ROM in all nodules ≥3 cm (13.1%) and ≥4 cm (20.9%) was lower than those <3 cm (19.6%) and <4 cm (19.9%; odds ratio [OR] = 0.72 [confidence interval (CI) 0.64-0.81] and OR = 0.85 [CI 0.77-0.95]). FNR in nodules ≥3 cm (7.2%) was not different from smaller nodules (5.7%; OR = 1.47 [CI 0.80-2.69]). FNR in nodules ≥4 cm (6.7%) was slightly higher than those <4 cm (4.5%; OR = 1.38 [CI 1.06-1.80]). The most frequently reported false-negative diagnosis was papillary thyroid carcinoma. Conclusions: Rates of malignancy and false-negative FNA results vary but, in most studies, are not higher in larger nodules. Patients with large, cytologically benign thyroid nodules need not undergo immediate surgical resection, as false-negative FNA rates are low and are expected to decrease in light of nomenclature revision of a subset of follicular variants of papillary thyroid carcinoma.
Background: Management of large thyroid nodules is controversial, as data are conflicting regarding overall rates of malignancy (ROM) in all nodules and frequency of false-negative fine-needle aspiration results (FNR) in cytologically benign nodules. This meta-analysis aimed to evaluate and compare ROM and FNR in small versus large nodules published in the literature. Methods: Articles indexed in PubMed, written in English, published electronically or in print on or prior to December 8 2017 were searched for "false negative thyroid size or cm" and "malignancy rates benign thyroid nodules." Three hundred fifty-two unique citations were identified. Multiple reviewers selected a final set of 35 articles that contained nodules stratified by size (3, 4, or 5 cm), with benign or all cytologic diagnoses, and with postsurgical histologic diagnoses. Multiple observers extracted data, including numbers of total, cytologically benign, and histologically malignant nodules. Size cutoffs of 3, 4, and/or 5 cm were analyzed in 14, 24, and 1 article, respectively. Results: ROM in all nodules ≥3 cm (13.1%) and ≥4 cm (20.9%) was lower than those <3 cm (19.6%) and <4 cm (19.9%; odds ratio [OR] = 0.72 [confidence interval (CI) 0.64-0.81] and OR = 0.85 [CI 0.77-0.95]). FNR in nodules ≥3 cm (7.2%) was not different from smaller nodules (5.7%; OR = 1.47 [CI 0.80-2.69]). FNR in nodules ≥4 cm (6.7%) was slightly higher than those <4 cm (4.5%; OR = 1.38 [CI 1.06-1.80]). The most frequently reported false-negative diagnosis was papillary thyroid carcinoma. Conclusions: Rates of malignancy and false-negative FNA results vary but, in most studies, are not higher in larger nodules. Patients with large, cytologically benign thyroid nodules need not undergo immediate surgical resection, as false-negative FNA rates are low and are expected to decrease in light of nomenclature revision of a subset of follicular variants of papillary thyroid carcinoma.
Authors: Muhammed Kizilgul; Rupendra Shrestha; Angela Radulescu; Maria R Evasovich; Lynn A Burmeister Journal: Endocrine Date: 2019-05-29 Impact factor: 3.633
Authors: María Molina-Vega; Carlos Antonio Rodríguez-Pérez; Ana Isabel Álvarez-Mancha; Gloria Baena-Nieto; María Riestra; Victoria Alcázar; Ana Reyes Romero-Lluch; Juan C Galofré; José C Fernández-García Journal: J Clin Med Date: 2019-12-09 Impact factor: 4.241
Authors: Hafiz M Zia-Ul-Hussnain; Oratile Kgosidialwa; Carmel Kennedy; Mark Quinn; Emma Dolan; Paul Deignan; Mark Sherlock; Chris J Thompson; Diarmuid Smith; James P O'Neill; Arnold Hill; Mary Leader; Helen Barrett; Cliona Ryan; Frank Keeling; Martina M Morrin; Amar Agha Journal: BMC Endocr Disord Date: 2022-04-15 Impact factor: 3.263
Authors: Samantha N Steinmetz-Wood; Amanda G Kennedy; Bradley J Tompkins; Matthew P Gilbert Journal: Int J Endocrinol Date: 2022-04-16 Impact factor: 2.803
Authors: Agnes Stephanie Harahap; Desty Gusti Sari; Marini Stephanie; Alvita Dewi Siswoyo; Litta Septina Mahmelia Zaid; Diani Kartini; Maria Francisca Ham; Tri Juli Edi Tarigan Journal: J Thyroid Res Date: 2022-01-11
Authors: Whitney Sutton; Joseph K Canner; Lisa M Rooper; Jason D Prescott; Martha A Zeiger; Aarti Mathur Journal: Am J Surg Date: 2020-06-02 Impact factor: 2.565